Serina Therapeutics (SER) investor relations material

Executive summary

• Clinical-stage biotech focused on neurological diseases, leveraging proprietary POZ drug delivery technology to improve efficacy and safety of therapeutics.

• Lead candidate SER-252 advanced to Phase 1b clinical trial for advanced Parkinson's disease after FDA clearance in January 2026; first patient dosed in February 2026.

• Completed enrollment and dosing in Cohort 1 of the Phase 1b registrational study for SER-252 ahead of schedule, with top-line data from the single-ascending-dose arm expected in the first half of 2027.

• Entered a development partnership with Gannet BioChem to support process development, scale-up, and manufacturing for SER-252.

• Appointed Farrell Simon, Pharm.D., to the Board of Directors, enhancing commercial and operational expertise.

Financial highlights

• Cash and cash equivalents were $23.0 million as of June 30, 2026, up from $3.1 million at December 31, 2025.

• Net loss attributable to common stockholders was $8.9 million for Q2 2026 and $15.9 million for the six months ended June 30, 2026, compared to $6.6 million and $11.4 million for the same periods in 2025.

• Total operating expenses increased to $6.8 million for Q2 2026 (from $5.7 million in Q2 2025) and $13.1 million for the six months (from $11.6 million in 2025).

• Research and development expenses rose to $3.8 million for Q2 2026 and $7.0 million for the six months, driven by increased clinical activity and headcount.

• General and administrative expenses were $3.0 million for Q2 2026 and $6.0 million for the six months, reflecting higher legal and compensation costs.

Outlook and guidance

• Management expects continued increases in R&D and G&A expenses as clinical programs advance and headcount grows.

• No product revenue expected until regulatory approval and commercialization of product candidates.

• Cash on hand is not expected to be sufficient to fund operations for twelve months from the financial statement issuance date; additional capital will be required.

• Top-line data from the single-ascending-dose arm of the SER-252 Phase 1b study is targeted for the first half of 2027.

• Continued focus on disciplined clinical execution and data generation to evaluate SER-252's potential for advanced Parkinson's disease.